A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)
Phase of Trial: Phase IV
Latest Information Update: 05 May 2019
Price : $35 *
At a glance
- Drugs Mirabegron (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Acronyms PILLAR
- Sponsors Astellas Pharma
- 31 Aug 2018 Results (n=888) presented at the 48th Annual Meeting of the International Continence Society.
- 19 Jan 2018 Status changed from active, no longer recruiting to completed.
- 28 Nov 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Dec 2017.